TerminatedNot Applicable

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Stopped: cohort C looked at feasibility of genetics \& protein to evaluate risk with a family hx of cancer or associated variant. Since few patients show these factors, this approach would not yield sufficient information to make inferences

United States215 participantsStarted 2020-05-04

Plain-language summary

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key inclusion criteria: * Female subject * 18 years of age or older Cohort A specific inclusion criteria: • Diagnosed with a pelvic mass Cohort B specific inclusion criteria: * Diagnosed with a pelvic mass * Undergoing genetic testing through our commercial offering Cohort C specific inclusion criteria: • Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer. Exclusion Criteria: * n/a

What they're measuring

OVA360

Timeframe: 12 months

Trial details

NCT IDNCT04668521

SponsorAspira Women's Health

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-15

View on ClinicalTrials.gov More Adnexal Mass trials